Top Markets
Coin of the day
Nuformix plc Nuformix plc

Nuformix plc

NFX
Pozycja w akcjach #20651
Nuformix plc operates in the field of pharmaceutical development for treating... Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Cena akcji
$0.00244926
Kapitalizacja rynkowa
$51.67K
Zmiana (1 dzień)
5.88%
Zmiana (1 rok)
110.15%
Kraj
GB
Handel Nuformix plc (NFX)

Kategoria

Zyski dla Nuformix plc (NFX)
Zyski w Sep 2025 TTM: $-5.28M
Według najnowszych raportów finansowych Nuformix plc, obecny zysk firmy wynosi $-5.28M. W roku 2024 firma osiągnęła zysk w wysokości $-4.88M, spadek w porównaniu do zysku z roku 2023, który wynosił $-754.56K. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Nuformix plc od 2014 do 2026
Zyski na koniec każdego roku
Rok Zyski Zmień
2026 (TTM) $-5.28M 494.63%
2025 $-888.01K -81.80%
2024 $-4.88M 546.72%
2023 $-754.56K -54.82%
2022 $-1.67M -11.94%
2021 $-1.90M 64.37%
2020 $-1.15M -51.92%
2019 $-2.40M -12.87%
2018 $-2.75M 220.48%
2017 $-859.40K 70.68%
2016 $-503.51K -206.04%
2014 $474.83K 0.00%
Zyski podobnych firm lub konkurentów
Firma Zyski Różnica w zyskach Kraj
$20.46B -387,521.89%
DK
$4.64B -88,033.93%
US
$5.23B -99,160.13%
US
$2.14B -40,584.12%
BE
$1.61B -30,671.66%
AU